Evonile Pharma Fund Raise of ₹900 Cr

Evonile Pharma Capital Structure Change

Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.

Value

₹884.8 Cr

Execution

Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026

Evonile Pharma Earnings Call Transcript: Key Takeaways

Q2 FY27 revenue ₹56.1 cr (-38% YoY) and PAT loss ₹77.5 cr, including ₹68 cr exceptional items. H1 revenue ₹159.9 cr (-10%). Transitioning to an independent branded pharma model; Minipress XL acquired.

Evonile Pharma Results Update

Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.

Evonile Pharma Investor Presentation: Key Takeaways

Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.

Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr

Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.

Key figure

Net loss ₹77.5 Cr

Novartis India Board Meeting Date

Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.

Pajson Agro India Fund Raise of ₹354.5 Cr

Pajson Agro's board approved a Rs.354.52 Crore preferential issue of 1,20,58,397 equity shares at Rs.294 each. Shareholder approval is sought at a meeting on 04-12-2026.

Value

₹354.5 Cr

Lloyds Metals & Energy Fund Raise

Lloyds Metals and Energy's board approved a fund raise, with the mode of financing yet to be decided. Investors should watch for the eventual issuance structure and size.

Shlokka Dyes Fund Raise of ₹24.5 Cr

Shlokka Dyes board approved a ₹24.50 Crore preferential issue of equity shares and warrants. Shareholder approval is pending at a November 28, 2026 meeting.

Value

₹24.50 Cr

Crescentis Capital Fund Raise of ₹79.62 Cr

Crescentis Capital's board approved the Letter of Offer for a rights issue of 1,02,08,129 shares at Rs.78 each. The issue aggregates to Rs.7,962.34 lakhs, or about Rs.79.62 Crore, assuming full subscription.

Value

₹79.62 Cr

Execution

Issue opening November 16, 2026; closing November 27, 2026; listing on or about December 3, 2026

Acetech E-Commerce Fund Raise of ₹40 Cr

Acetech E-Commerce approved a ₹40 Crore Rights Issue and 70% acquisition of Unique Cookware (₹10.41 Crore). Both decisions will fund expansion into cookware and allied products.

Value

₹40.00 Cr

Shree Pushkar Chemicals & Fertilisers Fund Raise of ₹45 Cr

Shree Pushkar's board approved a preferential issue of 854,060 convertible warrants to Punit Makharia. The issue would raise about Rs.45.00 Crore at Rs.527 per warrant.

Value

₹45.00 Cr